The latest price target for Longboard Pharmaceuticals (NASDAQ:LBPH) was reported by HC Wainwright & Co. on October 15, 2024. The analyst firm set a price target for $60.00 expecting LBPH to rise to within 12 months (a possible 0.35% upside). 38 analyst firms have reported ratings in the last year.

The latest analyst rating for Longboard Pharmaceuticals (NASDAQ:LBPH) was provided by HC Wainwright & Co., and Longboard Pharmaceuticals downgraded their neutral rating.

There is no last upgrade for Longboard Pharmaceuticals

The last downgrade for Longboard Pharmaceuticals Inc happened on October 15, 2024 when HC Wainwright & Co. changed their price target from $80 to $60 for Longboard Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Longboard Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Longboard Pharmaceuticals was filed on October 15, 2024 so you should expect the next rating to be made available sometime around October 15, 2025.

While ratings are subjective and will change, the latest Longboard Pharmaceuticals (LBPH) rating was a downgraded with a price target of $80.00 to $60.00. The current price Longboard Pharmaceuticals (LBPH) is trading at is $59.79, which is out of the analyst’s predicted range.